Skip to main content

Solenis chooses home turf for R&D expansion

Aided by $4 million in state grant funds, Solenis is to move its R&D operations to Building 713 at Chestnut Run Innovation & Science Park (CRISP, pictured) in its home state of Delaware. This $40 million expansion comes “in response to increasing market demand for its sustainability-focused products and expertise and with an eye toward long-term growth”, the company said.

WuXi STA expands into Europe

China-based pharmaceutical CDMO WuXi STA has completed the acquisition of a drug product manufacturing facility in Couvet, Switzerland, from Bristol-Myers Squibb, as announced earlier in the year. The site is WuXi STA’s first in Europe. It makes tablets and capsules.

Through this transaction, WuXi STA has increased its global presence to eight R&D and manufacturing sites across Asia, North America and Europe, including a pharmaceutical clinical and commercial manufacturing complex on a 78-hectare campus at Middletown, Delaware, that was announced in early July.

PFAS claims in Delaware settled

DuPont and the companies that used to be part of it, Chemours and Corteva, have reached a settlement with the Delaware Department of Justice. Under this, they are held responsible for decades of damage done to Delaware’s environment by per- and polyfluoroalkyl substances (PFASs).

The agreement has avoided a potential lawsuit for historic contamination by PFASs in Delaware, which remains DuPont’s headquarters. This had impacted waterways and groundwater located in each of the state’s three counties.

Delaware for WuXi STA campus

Chinese CDMO WuXi STA is to build a new pharmaceutical clinical and commercial manufacturing complex on a 78-hectare campus in Middletown, Delaware. This has been supported by the Delaware Prosperity Partnership, other state departments and local government bodies, and received grants from the Delaware Strategic Fund.

Round one to DuPont over Chemours in legal battle

The first step in ongoing litigation in the US between Chemours and its parent firm DuPont over the cost of environmental liabilities relating to historic pollution caused by per- and polyfluoroalkyl substances (PFASs) went DuPont’s way on 2 April. Chemours has said that it will appeal to the Delaware Supreme Court.

Chemours opens 'Discovery Hub'

Chemours has formally inaugurated its new innovation centre, the Chemours Discovery Hub, on the University of Delaware’s Science, Technology & Advanced Research (STAR) Campus in Newark.
Subscribe to Delaware